Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)

• Autores principales: Jennifer Soung (Autor), Jennifer C. Cather (Autor), Melinda Gooderham (Autor), Caitriona Ryan (Autor), Najwa Somani (Autor), Meghan Feely (Autor), Kyoungah See (Autor), Russel Burge (Autor), Mohamed Elrayes (Autor), Gaia Gallo (Autor), April W. Armstrong (Autor)
• Formato: Libro
• Publicado: Wiley, 2023-06-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Background People with genital psoriasis may avoid close social interactions (hugs, handshakes, kisses, touching others, or being touched), which can have a significant impact on quality of life. Ixekizumab, an interleukin 17A antagonist, demonstrated rapid and persistent improvement in mod...